We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Hepatocellular carcinoma, or hepatocarcinoma, is the most common type of primary liver cancer and the leading cause of death in patients with liver cirrhosis. The disease is two to three times more prevalent in men than in women and develops in over 80% of cases in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or C, alcohol consumption, or fatty liver disease.
Hepatocellular carcinoma is one of the cancers with the highest mortality rate, being the third leading cause of cancer-related death.
In early stages, the disease is asymptomatic, meaning there are no clinical manifestations. In advanced stages, some of the following symptoms may appear:
Abdominal pain or tenderness
Abdominal enlargement (ascites)
Yellowing of the skin or eyes (jaundice)
Tendency to bleed or form bruises
Unexplained weight loss
In more than 80% of cases, hepatocellular carcinoma occurs in patients with underlying liver disease, especially liver cirrhosis.
Screening is important for diagnosing the disease at early stages, which is the ideal time to apply curative-intent treatment.
The diagnostic tests and procedures used depend on the patient profile:
Patients at risk with known liver disease: Screening should be performed every six months using ultrasound. If a nodule is detected, contrast imaging tests such as CT scan or contrast-enhanced MRI are performed to confirm the diagnosis. In some cases, a liver biopsy is required, which involves extracting tumor tissue.
Patients with unknown predisposing factors and not in a screening program: Usually diagnosed after the appearance of initial symptoms, using the following diagnostic tests:
Imaging tests such as CT scans and MRI
Tumor biopsy to extract liver tissue for histopathological examination
Treatment for hepatocellular carcinoma varies for each patient, depending on tumor burden, liver function, and overall health status.
The most commonly used treatments are:
Surgical: Resection surgery and liver transplantation, applicable in early stages
Locoregional: Aimed at destroying tumor cells through direct ablation (radiofrequency ablation, microwave ablation, cryoablation, etc.) or via endovascular methods (transarterial chemoembolization or radioembolization)
Systemic: Used mainly in advanced stages, currently including immunotherapy drugs and tyrosine kinase inhibitors
Survival in advanced stages has improved significantly thanks to the successful results of treatment combinations that include immunotherapy. Many patients have benefited and continue to benefit from these treatments before their official approval and commercialization through participation in clinical trials.
The most common diagnostic tests for this condition are ultrasound, CT scan, contrast-enhanced MRI, and biopsy. Blood tests are also used both for diagnosis and follow-up in daily clinical practice.
The best way to prevent hepatocellular carcinoma is to avoid risk factors, such as alcohol consumption and smoking, control diabetes (a key component of metabolic syndrome associated with fatty liver disease), and prevent or treat hepatitis B and C infections.
Medical Oncology, General Hospital
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.